Navellier & Associates Inc Dexcom Inc Transaction History

Navellier & Associates Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 09, 2021	SELL	$80.99 - $107.93 $442,367 - $589,513	-5,462 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$84.79 - $104.74 $324,406 - $400,735	-3,826 Reduced 41.19%	5,462 $1.96 Million
Q4 2020 Feb 05, 2021	SELL	$78.0 - $104.5 $464,646 - $622,506	-5,957 Reduced 39.08%	9,288 $3.43 Million
Q3 2020 Nov 09, 2020	SELL	$95.51 - $112.95 $38,968 - $46,083	-408 Reduced 2.61%	15,245 $6.28 Million
Q2 2020 Aug 12, 2020	SELL	$62.68 - $105.34 $501 - $842	-8 Reduced 0.05%	15,653 $6.35 Million
Q1 2020 May 13, 2020	SELL	$47.79 - $75.63 $101,219 - $160,184	-2,118 Reduced 11.91%	15,661 $4.22 Million
Q4 2019 Feb 12, 2020	SELL	$36.62 - $57.29 $27,538 - $43,082	-752 Reduced 4.06%	17,779 $3.89 Million
Q3 2019 Oct 16, 2019	SELL	$35.53 - $43.8 $12,932 - $15,943	-364 Reduced 1.93%	18,531 $2.77 Million
Q2 2019 Jul 17, 2019	SELL	$27.84 - $38.92 $9,660 - $13,505	-347 Reduced 1.8%	18,895 $2.83 Million
Q1 2019 May 15, 2019	SELL	$28.07 - $38.18 $6,035 - $8,208	-215 Reduced 1.11%	19,242 $2.29 Million
Q4 2018 Jan 15, 2019	BUY	$26.99 - $37.37 $525,144 - $727,108	19,457 New	19,457 $2.33 Million

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Navellier & Associates Inc with notifications on news.